These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38006445)

  • 21. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
    Zheng X; Lin J; Xiong J; Guan Y; Lan B; Li Y; Gao X; Fei Z; Chen L; Chen L; Chen L; Chen G; Guo Z; Yi X; Cao W; Ai X; Zhou C; Li X; Zhao J; Yan X; Yu Q; Si L; Chen Y; Chen C
    BMC Cancer; 2023 Jul; 23(1):686. PubMed ID: 37479966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
    Yang SR; Gedvilaite E; Ptashkin R; Chang J; Ziegler J; Mata DA; Villafania LB; Nafa K; Hechtman JF; Benayed R; Zehir A; Benhamida J; Arcila ME; Mandelker D; Rudin CM; Paik PK; Drilon A; Schoenfeld AJ; Ladanyi M
    J Thorac Oncol; 2024 Mar; 19(3):409-424. PubMed ID: 37838086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
    Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
    Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low microsatellite instability: A distinct instability type in gastric cancer?
    Kohlruss M; Chakraborty S; Hapfelmeier A; Jesinghaus M; Slotta-Huspenina J; Novotny A; Sisic L; Gaida MM; Ott K; Weichert W; Pfarr N; Keller G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17727-17737. PubMed ID: 37819581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
    Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab┬▒Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
    Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
    Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amplification of the human epidermal growth factor receptor 2 (
    Huang H; Wang Z; Li Y; Zhao Q; Niu Z
    J Gastrointest Oncol; 2021 Apr; 12(2):377-387. PubMed ID: 34012633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
    Li Z; Jia Y; Zhu H; Xing X; Pang F; Shan F; Li S; Wang D; Zhao F; Ma T; Wang S; Ji J
    Gastric Cancer; 2021 Nov; 24(6):1342-1354. PubMed ID: 34406546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.
    Zhang Q; Zhang J; Liu Z; Wang J; Wang F; Wang T; Shi F; Su J; Zhao Y
    Drug Des Devel Ther; 2023; 17():3507-3522. PubMed ID: 38046281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly sensitive duplex MSI test and BAT40 germline polymorphism.
    Kang SY; Kim KM
    APMIS; 2021 Oct; 129(10):607-615. PubMed ID: 34342050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.